Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
23 Apr 24
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
PRE 14A
Preliminary proxy
12 Apr 24
EFFECT
Notice of effectiveness
11 Apr 24
S-3
Shelf registration
29 Mar 24
8-K
Unregistered Sales of Equity Securities
22 Mar 24
S-8
Registration of securities for employees
26 Feb 24
10-K
2023 FY
Annual report
26 Feb 24
8-K
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
26 Feb 24
8-K
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement
14 Feb 24
8-K
Other Events
11 Dec 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results
2 Nov 23
S-8
Registration of securities for employees
8 Aug 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results
8 Aug 23
8-K
Entry into a Material Definitive Agreement
8 Jun 23
424B5
Prospectus supplement for primary offering
8 Jun 23
8-K
Departure of Directors or Certain Officers
7 Jun 23
424B5
Prospectus supplement for primary offering
6 Jun 23
8-K
Other Events
6 Jun 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Cogent Biosciences Reports Recent Business Highlights and First Quarter
9 May 23
ARS
2022 FY
Annual report to shareholders
25 Apr 23
DEFA14A
Additional proxy soliciting materials
25 Apr 23
DEF 14A
Definitive proxy
25 Apr 23
S-8
Registration of securities for employees
14 Mar 23
10-K
2022 FY
Annual report
14 Mar 23
8-K
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
14 Mar 23
S-3ASR
Automatic shelf registration
10 Feb 23
8-K
Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating
12 Dec 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results
14 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
8-K
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2022 Financial Results
9 Aug 22
8-K/A
Entry into a Material Definitive Agreement
16 Jun 22
8-K
Entry into a Material Definitive Agreement
15 Jun 22
424B5
Prospectus supplement for primary offering
15 Jun 22
FWP
Free writing prospectus
13 Jun 22
Latest ownership filings
4
Karen Jean Ferrante
2 Apr 24
SC 13D/A
Fairmount Funds Management LLC
1 Apr 24
4
Change in insider ownership
1 Apr 24
SC 13D/A
Fairmount Funds Management LLC
27 Mar 24
SC 13D/A
Fairmount Funds Management LLC
16 Feb 24
4
Change in insider ownership
16 Feb 24
SC 13G/A
Venrock Healthcare Capital Partners II, L.P.
14 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
SC 13G/A
COMMODORE CAPITAL LP
14 Feb 24
SC 13G
Kynam Capital Management, LP
14 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
TCG Crossover GP I, LLC
9 Feb 24
SC 13G
FMR LLC
9 Feb 24
SC 13G
SUVRETTA CAPITAL MANAGEMENT, LLC
5 Feb 24
SC 13G/A
BlackRock Inc.
26 Jan 24
4
John Edward Robinson
25 Jan 24
4
Evan Kearns
25 Jan 24
4
Jessica Sachs
25 Jan 24
4
Andrew R Robbins
25 Jan 24
4
John L. Green
25 Jan 24
SC 13G/A
STATE STREET CORP
23 Jan 24
4
Karen Jean Ferrante
4 Jan 24
4
Matthew Ros
4 Jan 24
4
Matthew Ros
3 Oct 23
4
Karen Jean Ferrante
3 Oct 23
4
Karen Jean Ferrante
5 Jul 23
4
Matthew Ros
5 Jul 23
4
Change in insider ownership
13 Jun 23
SC 13D/A
Fairmount Funds Management LLC
13 Jun 23
4
Arlene Morris
8 Jun 23
4
CHRISTOPHER W. CAIN
8 Jun 23
4
Karen Jean Ferrante
8 Jun 23
4
Todd Shegog
8 Jun 23
4
Matthew Ros
8 Jun 23
4
Peter Evan Harwin
8 Jun 23
SC 13G
Point72 Asset Management, L.P.
1 Jun 23
4
Karen Jean Ferrante
4 Apr 23
4
Matthew Ros
4 Apr 23
4
John Edward Robinson
15 Feb 23